BS01 in Patients With Retinitis Pigmentosa

Recruiting now · Phase 1/Phase 2

Conditions studied: Retinitis Pigmentosa

In brief

A Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa

Key facts

Study ID

NCT04278131

Run by

Bionic Sight LLC

People needed

20

Starts

2020-02-06

Expected to finish

2029-12-30

Last updated by the study team

2026-01-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed diagnosis of retinitis pigmentosa
• At least one eye with vision no better than 20/160 visual acuity on the EDTRS scale or, for patients with peripheral vision loss, a visual field no greater than 30°.

You may not qualify if…

• Prior receipt of any AAV gene therapy product
• Large amplitude nystagmus

Where it is running

• New Jersey Retina — Teaneck, New Jersey, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.